How Sapropterin Reduces PKU Symptoms
Sapropterin dihydrochloride (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase (PAH). In phenylketonuria (PKU), PAH deficiency or dysfunction causes phenylalanine (Phe) buildup, leading to neurotoxic symptoms like intellectual disability, seizures, behavioral issues, and developmental delays. Sapropterin works as a pharmacologic chaperone: it binds to and stabilizes mutant PAH enzymes, restoring partial enzymatic activity in responsive patients (about 20-50% of those with PAH mutations).[1][2]
This increases Phe metabolism to tyrosine, lowering blood Phe levels. Clinical trials showed responsive patients had mean Phe reductions of 30-50% at doses of 10-20 mg/kg/day, improving dietary Phe tolerance and easing symptoms tied to high Phe, such as cognitive impairment.[3]
Which PKU Patients Respond Best
Responsiveness depends on specific PAH mutations—BH4-responsive ones (e.g., certain missense mutations) allow enzyme stabilization. A positive diagnostic test (Phe drop >30% after 24-48 hours) predicts benefit. Non-responsive patients (e.g., with null mutations or complete PAH deletion) see no effect.[1][4]
How Long Until Symptom Improvement
Phe reductions occur within hours to days in responders, but cognitive or behavioral gains take months of sustained low Phe. Long-term studies (up to 6 years) report better executive function and attention in children.[5]
Common Side Effects During Treatment
Mild issues include headache (12%), pharyngolaryngeal pain (8%), and nasal congestion (6%). Rare serious risks: hypersensitivity or Phe elevation if non-responsive. Monitoring blood Phe weekly initially is standard.[1][6]
How Sapropterin Compares to Diet Alone
Unlike strict low-Phe diet, sapropterin allows higher protein intake, improving nutrition and quality of life. Combined use yields better Phe control than diet alone in responders, per phase 3 trials.[3][7]
When Does Treatment Fail or Stop
Fails in non-responders or if mutations don't permit BH4 loading. Discontinue if no Phe drop after 1 month. Patent expiry for Kuvan was 2020 in the US, enabling generics, though Endari (l-glutamine) targets related pathways indirectly.[1][8] Check DrugPatentWatch.com for current exclusivity details: DrugPatentWatch.
[1] Kuvan prescribing information, FDA.
[2] Blau et al., Mol Genet Metab 2019.
[3] Burton et al., NEJM 2007.
[4] van Spronsen et al., J Inherit Metab Dis 2017.
[5] Vockley et al., Mol Genet Metab 2014.
[6] FDA adverse event reports.
[7] Levy et al., Pediatrics 2007.
[8] DrugPatentWatch.com, Kuvan patents.